TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomised Trial of 0.025 Wire Guided Cannulation Versus Current Practice 0.035 Wire Guided Cannulation
Brief Summary: The aim of this study is to determine whether using a smaller wire results in a higher success rate at endoscopic retrograde cholangiopancreatography (ERCP), and lower incidence of adverse events


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Indomethacin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo suppositories | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo suppositories; Assigned to Arm(s): 2
B: Arm Label: A (NS+Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline, Drug: Placebo | Arm Label: B (NS+IND); Type: ACTIVE_COMPARATOR; Interventions: Drug: Indomethacin, Drug: Normal Saline | Arm Label: C (LR+Placebo); Type: ACTIVE_COMPARATOR; Interventions: Drug: Lactated Ringer's Solution, Drug: Placebo | Arm Label: D (LR+IND); Type: EXPERIMENTAL; Interventions: Drug: Indomethacin, Drug: Lactated Ringer's Solution | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): B (NS+IND), D (LR+IND) | Intervention Type: DRUG; Name: Lactated Ringer's Solution; Assigned to Arm(s): C (LR+Placebo), D (LR+IND) | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): A (NS+Placebo), B (NS+IND) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A (NS+Placebo), C (LR+Placebo)
C: Intervention Type: PROCEDURE; Name: Double guide wire technique; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Standard bile duct cannulation; Assigned to Arm(s): N/A
D: Arm Label: 0.035 guidewire; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional 0.035 guidewire | Arm Label: Olympus Visiglide 0.025 guidewire; Type: ACTIVE_COMPARATOR; Interventions: Device: Olympus Visiglide 0.025 guidewire | Intervention Type: DEVICE; Name: Conventional 0.035 guidewire; Assigned to Arm(s): 0.035 guidewire | Intervention Type: DEVICE; Name: Olympus Visiglide 0.025 guidewire; Assigned to Arm(s): Olympus Visiglide 0.025 guidewire

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Single Embryo Transfer of a Euploid Embryo Versus Double Embryo Transfer: A Randomized Controlled Trial
Brief Summary: This study seeks to compare the pregnancy and delivery rates of patients who undergo a single embryo transfer, when the embryo has been tested and determined to be chromosomally normal, with pregnancy and delivery rates of patients who undergo a two (2) embryo transfer of untested embryos.


Options:
A: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Other: Preimplantation Genetic Screening by NGS | Arm Label: Group B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Preimplantation Genetic Screening by NGS; Assigned to Arm(s): Group A
B: Arm Label: Single Embryo Transfer; Type: OTHER; Interventions: Other: Single Embryo Transfer | Arm Label: Double Embryo Transfer; Type: OTHER; Interventions: Other: Double embryo transfer | Intervention Type: OTHER; Name: Single Embryo Transfer; Assigned to Arm(s): Single Embryo Transfer | Intervention Type: OTHER; Name: Double embryo transfer; Assigned to Arm(s): Double Embryo Transfer
C: Arm Label: Control (no PGD); Type: N/A; Interventions: N/A | Arm Label: Case (PGD); Type: N/A; Interventions: N/A
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Genetic: single embryo transfer without aneuploidy screening | Arm Label: B; Type: EXPERIMENTAL; Interventions: Genetic: single embryo transfer with aneuploidy screening | Intervention Type: GENETIC; Name: single embryo transfer without aneuploidy screening; Assigned to Arm(s): A | Intervention Type: GENETIC; Name: single embryo transfer with aneuploidy screening; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Trial of Plasma Exchange or High Dose Methyl Prednisolone as Adjunctive Therapy for Severe Renal Vasculitis
Brief Summary: The purpose of this study is to test whether additional therapy with plasma exchange improves the chances of kidney recovery in severe kidney vasculitis.


Options:
A: Arm Label: mycophenolate mofetil; Type: EXPERIMENTAL; Interventions: Drug: mycophenolate mofetil | Arm Label: cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): mycophenolate mofetil | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): cyclophosphamide
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Plasma exchange | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous methyl prednisolone, Drug: Methyl prednisolone | Intervention Type: PROCEDURE; Name: Plasma exchange; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Intravenous methyl prednisolone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Methyl prednisolone; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PROgenitor Cell Release Plus Exercise to Improve functionaL Performance in PAD: The PROPEL Study
Brief Summary: The PROPEL study will test the hypothesis that GM-CSF combined with supervised treadmill exercise will significantly improve functional performance in patients with PAD more than GM-CSF alone or supervised treadmill exercise alone. In addition to identifying novel therapeutic options for patients with PAD, the current proposal is expected to identify mechanisms by which functional impairment is improved in patients with PAD.


Options:
A: Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: NV1FGF 16 mg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 32 mg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): NV1FGF 16 mg, NV1FGF 32 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A
C: Arm Label: A: GM-CSF + supervised treadmill exercise therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Supervised Treadmill Exercise Therapy, Drug: granulocyte macrophage colony stimulating factor (GM-CSF) | Arm Label: B: GM-CSF + attention control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Health education sessions (Control), Drug: granulocyte macrophage colony stimulating factor (GM-CSF) | Arm Label: C: placebo + supervised exercise therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Treadmill Exercise Therapy | Arm Label: D: placebo + attention control group; Type: PLACEBO_COMPARATOR; Interventions: Other: Health education sessions (Control) | Intervention Type: BEHAVIORAL; Name: Supervised Treadmill Exercise Therapy; Assigned to Arm(s): A: GM-CSF + supervised treadmill exercise therapy, C: placebo + supervised exercise therapy | Intervention Type: OTHER; Name: Health education sessions (Control); Assigned to Arm(s): B: GM-CSF + attention control group, D: placebo + attention control group | Intervention Type: DRUG; Name: granulocyte macrophage colony stimulating factor (GM-CSF); Assigned to Arm(s): A: GM-CSF + supervised treadmill exercise therapy, B: GM-CSF + attention control group
D: Arm Label: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ad2/HIF-1α/VP16 | Arm Label: Middle Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ad2/HIF-1α/VP16 | Arm Label: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ad2/HIF-1α/VP16 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline (Placebo Control) | Intervention Type: BIOLOGICAL; Name: Ad2/HIF-1α/VP16; Assigned to Arm(s): Low Dose | Intervention Type: BIOLOGICAL; Name: Ad2/HIF-1α/VP16; Assigned to Arm(s): Middle Dose | Intervention Type: BIOLOGICAL; Name: Ad2/HIF-1α/VP16; Assigned to Arm(s): High Dose | Intervention Type: OTHER; Name: Saline (Placebo Control); Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Postpartum Prophylaxis With Short Course Magnesium Sulfate in Severe Preeclampsia: a Randomized Clinical Trial
Brief Summary: Magnesium sulfate is the ideal drug for seizures prophilaxis in preeclampsia. The ideal duration of this treatment after delivery is still to be established. The hypothesis is that in stable patients a shorter course of treatment is possible without prejudice to the mother.


Options:
A: Arm Label: Postpartum Magnesium sulfate; Type: EXPERIMENTAL; Interventions: Drug: Magnesium Sulfate | Arm Label: No postpartum treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Magnesium Sulfate; Assigned to Arm(s): Postpartum Magnesium sulfate
B: Arm Label: IV; Type: ACTIVE_COMPARATOR; Interventions: Other: IV administration, Drug: Magnesium Sulfate | Arm Label: Springfusor; Type: EXPERIMENTAL; Interventions: Device: Springfusor infusion pump, Drug: Magnesium Sulfate | Intervention Type: DEVICE; Name: Springfusor infusion pump; Assigned to Arm(s): Springfusor | Intervention Type: OTHER; Name: IV administration; Assigned to Arm(s): IV | Intervention Type: DRUG; Name: Magnesium Sulfate; Assigned to Arm(s): IV, Springfusor
C: Arm Label: 12 hours of magnesium sulfate; Type: EXPERIMENTAL; Interventions: Drug: Magnesium sulfate 12 hours | Arm Label: 24 hours of magnesium sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium sulfate 24 hours | Intervention Type: DRUG; Name: Magnesium sulfate 12 hours; Assigned to Arm(s): 12 hours of magnesium sulfate | Intervention Type: DRUG; Name: Magnesium sulfate 24 hours; Assigned to Arm(s): 24 hours of magnesium sulfate
D: Intervention Type: DRUG; Name: abbreviation of magnesium sulfate therapy (12 hours versus the traditional 24 hours after delivery); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Weight Loss on Portal Pressure in Patients With Compensated Cirrhosis and Overweight/Obesity
Brief Summary: Overweight/obesity is increasing both in the general population and in patients with cirrhosis. In compensated patients with cirrhosis increased BMI is a risk factor for clinical decompensation independent of liver function and portal pressure. Nonetheless, patients with cirrhosis and obesity show a progressive increase in portal pressure, which might explain their increased risk of complications. Since obesity is a potentially modifiable risk factor, we designed this proof-of-concept study to assess the effects of weight loss (obtained by 4 months of diet and exercise) on portal pressure in patients with compensated cirrhosis and overweight/obesity.


Options:
A: Arm Label: Home based aerobic exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Home based Aerobic exercise training | Arm Label: Usual Care group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Home based Aerobic exercise training; Assigned to Arm(s): Home based aerobic exercise
B: Arm Label: Physical training - No encephalopathy; Type: EXPERIMENTAL; Interventions: Other: Physical training, Other: Diet intervention | Arm Label: Control - No encephalopathy; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet intervention | Arm Label: Physical training - Early encephalopathy; Type: EXPERIMENTAL; Interventions: Other: Physical training, Other: Diet intervention | Arm Label: Control - Early encephalopathy; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet intervention | Intervention Type: OTHER; Name: Physical training; Assigned to Arm(s): Physical training - Early encephalopathy, Physical training - No encephalopathy | Intervention Type: OTHER; Name: Diet intervention; Assigned to Arm(s): Control - Early encephalopathy, Control - No encephalopathy, Physical training - Early encephalopathy, Physical training - No encephalopathy
C: Arm Label: Diet+Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Diet + exercise | Intervention Type: BEHAVIORAL; Name: Diet + exercise; Assigned to Arm(s): Diet+Exercise
D: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Video-assisted Hyperthermic Pleural Chemoperfusion Versus Bed-side Talc Slurry Pleurodesis for Refractory Malignant Pleural Effusions.
Brief Summary: Aim of this study is to compare two methods of pleurodesis for refractory malignant pleural effusions, in terms of safety and efficacy.


Options:
A: Arm Label: VATS hyperthermic pleural chemoperfusion; Type: ACTIVE_COMPARATOR; Interventions: Procedure: VATS hyperthermic chemoperfusion | Arm Label: Bedside talc slurry pleurodesis; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Bedside talc slurry pleurodesis | Intervention Type: PROCEDURE; Name: VATS hyperthermic chemoperfusion; Assigned to Arm(s): VATS hyperthermic pleural chemoperfusion | Intervention Type: PROCEDURE; Name: Bedside talc slurry pleurodesis; Assigned to Arm(s): Bedside talc slurry pleurodesis
B: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Procedure: therapeutic videothoracoscopy | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Other: talc, Procedure: therapeutic thoracoscopy | Intervention Type: OTHER; Name: talc; Assigned to Arm(s): Arm II | Intervention Type: PROCEDURE; Name: therapeutic thoracoscopy; Assigned to Arm(s): Arm II | Intervention Type: PROCEDURE; Name: therapeutic videothoracoscopy; Assigned to Arm(s): Arm I
C: Arm Label: EDIT Management; Type: EXPERIMENTAL; Interventions: Procedure: EDIT Management | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Chest drain and talc pleurodesis | Intervention Type: PROCEDURE; Name: EDIT Management; Assigned to Arm(s): EDIT Management | Intervention Type: PROCEDURE; Name: Chest drain and talc pleurodesis; Assigned to Arm(s): Standard Care
D: Arm Label: pleurectomy/decortication; Type: EXPERIMENTAL; Interventions: Procedure: pleurectomy/decortication | Arm Label: indwelling pleural catheter; Type: EXPERIMENTAL; Interventions: Procedure: indwelling pleural catheter | Intervention Type: PROCEDURE; Name: pleurectomy/decortication; Assigned to Arm(s): pleurectomy/decortication | Intervention Type: PROCEDURE; Name: indwelling pleural catheter; Assigned to Arm(s): indwelling pleural catheter

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Isometric Muscle Training of the Spine Musculature in Patients With Spinal Bony Metastases Under Radiation Therapy
Brief Summary: Standard indications for palliative radiation of bony metastases include pain, spinal cord compression, and impending pathologic fractures.

Palliative radiation therapy serves to reduce pain, improve quality of life, and avoid complications. Tailored training of the paravertebral musculature may support radiation therapy and improve above named factors. DISPO was designed to investigate the impact of tailored physical exercise in patients with vertebral metastases as compared to manual therapy (massage etc.). The trial includes patients with painful bony metastases, patients with spinal cord compression or impending pathological fractures are excluded. The investigations are carried out in a prospective randomized controlled phase-II parallel group design.


Options:
A: Arm Label: Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: RePCa A | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: RePCa A | Intervention Type: BEHAVIORAL; Name: RePCa A; Assigned to Arm(s): Control, Rehabilitation
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Behavior Change | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise Behavior Change; Assigned to Arm(s): 1
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: exercise | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: exercise; Assigned to Arm(s): A
D: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Study Group; Type: EXPERIMENTAL; Interventions: Other: Domiciliary exercises for the upper limbs | Intervention Type: OTHER; Name: Domiciliary exercises for the upper limbs; Assigned to Arm(s): Study Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Isometric Muscle Training of the Spine Musculature in Patients With Spinal Bony Metastases Under Radiation Therapy
Brief Summary: Standard indications for palliative radiation of bony metastases include pain, spinal cord compression, and impending pathologic fractures.

Palliative radiation therapy serves to reduce pain, improve quality of life, and avoid complications. Tailored training of the paravertebral musculature may support radiation therapy and improve above named factors. DISPO was designed to investigate the impact of tailored physical exercise in patients with vertebral metastases as compared to manual therapy (massage etc.). The trial includes patients with painful bony metastases, patients with spinal cord compression or impending pathological fractures are excluded. The investigations are carried out in a prospective randomized controlled phase-II parallel group design.


Options:
A: Arm Label: Active video games; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise based on active video gaming | Arm Label: Routine care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise based on active video gaming; Assigned to Arm(s): Active video games
B: Arm Label: Exercise (EX); Type: EXPERIMENTAL; Interventions: Other: EXERCISE (EX) | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Care | Intervention Type: OTHER; Name: EXERCISE (EX); Assigned to Arm(s): Exercise (EX) | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: exercise | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: exercise; Assigned to Arm(s): A
D: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical exercise, Other: best supportive care | Arm Label: No exercise; Type: OTHER; Interventions: Other: best supportive care | Intervention Type: BEHAVIORAL; Name: Physical exercise; Assigned to Arm(s): Exercise | Intervention Type: OTHER; Name: best supportive care; Assigned to Arm(s): Exercise, No exercise

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Detection and Progression of Subclinical Atherosclerosis and Its Relationship to Coronary Risk Factors
Brief Summary: The overall objective of this study is to characterize the prevalence and progression rate of subclinical atherosclerotic lesions and to study their association to the imaging characteristics of atheroma plaques and to the presence of genetic, epigenetic, metabolomic, and environmental factors, including dietary habits, physical activity, biorhythms, psychosocial characteristics, and exposure to environmental pollutants


Options:
A: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education
B: Arm Label: High fat low carbohydrate diet; Type: EXPERIMENTAL; Interventions: Dietary Supplement: High fat low carbohydrate diet | Arm Label: Low fat high carbohydrate diet; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low fat high carbohydrate diet | Intervention Type: DIETARY_SUPPLEMENT; Name: High fat low carbohydrate diet; Assigned to Arm(s): High fat low carbohydrate diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Low fat high carbohydrate diet; Assigned to Arm(s): Low fat high carbohydrate diet
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ADA 2003 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low Glycemic index (LGI) diet | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MUFA diet | Intervention Type: BEHAVIORAL; Name: MUFA diet; Assigned to Arm(s): 3 | Intervention Type: BEHAVIORAL; Name: ADA 2003; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low Glycemic index (LGI) diet; Assigned to Arm(s): 2
D: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
Brief Summary: A protocol to extend the assessment of the safety and efficacy of taliglucerase alfa in pediatric subjects (2 to \<18 years old) with symptoms and clinical manifestations of Gaucher disease who completed treatment in Protocols PB-06-002 (switchover study from imiglucerase) or PB-06-005 (naïve treatment with taliglucerase alfa).


Options:
A: Arm Label: Taliglucerase alfa 30 units/kg; Type: EXPERIMENTAL; Interventions: Drug: Taliglucerase alfa | Arm Label: Taliglucerase alfa 60 units/kg; Type: EXPERIMENTAL; Interventions: Drug: Taliglucerase alfa | Intervention Type: DRUG; Name: Taliglucerase alfa; Assigned to Arm(s): Taliglucerase alfa 30 units/kg, Taliglucerase alfa 60 units/kg
B: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Eliglustat tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eliglustat tartrate; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Investigational; Type: EXPERIMENTAL; Interventions: Drug: Eliglustat tartrate | Arm Label: Imiglucerase; Type: ACTIVE_COMPARATOR; Interventions: Drug: Imiglucerase | Intervention Type: DRUG; Name: Eliglustat tartrate; Assigned to Arm(s): Investigational | Intervention Type: DRUG; Name: Imiglucerase; Assigned to Arm(s): Imiglucerase
D: Arm Label: 60 Units/kg; Type: EXPERIMENTAL; Interventions: Drug: Taliglucerase alfa | Arm Label: 30 Units/kg; Type: EXPERIMENTAL; Interventions: Drug: Taliglucerase alfa | Intervention Type: DRUG; Name: Taliglucerase alfa; Assigned to Arm(s): 30 Units/kg, 60 Units/kg

Answer: D